The American Society of Hematology (ASH) is undertaking a multifaceted initiative to address the burden of sickle cell disease (SCD), both in the United States and globally. Throughout the initiative, ASH has engaged a broad array of stakeholders to identify the highest priorities needed to improve outcomes for individuals with SCD.
Explore ASH’s SCD priorities outlined below, and discover the steps ASH has taken and continues to explore to make a significant difference in SCD access to care, research, and global issues.
Founded by ASH in 2016 to help amplify the voice of the SCD stakeholder community to improve outcomes for individuals with SCD
An overview of ASH activities to advance sickle cell disease and sickle cell trait research
ASH is committed to ensuring that individuals with SCD have access to high quality of care and provides SCD education, training, and resources for clinicians
ASH works with federal agencies and the U.S. Congress to help enhance and expand government activities in SCD research, training, and services
Expanding screening, care, and awareness for SCD worldwide
Resources designed to increase understanding of sickle cell trait
Sickle Cell Disease Coalition
In 2016, the Sickle Cell Disease Coalition (SCDC) was founded to help amplify the voice of the SCD stakeholder community, promote awareness, and improve outcomes for individuals with SCD.
The SCDC’s growing membership of more than 50 groups includes public health, research, and provider organizations; patient groups; federal agencies; industry representatives; and foundations. The SCDC is focused on coordinating efforts to produce the greatest impact for individuals with SCD.back to top
SCD Research Priorities
ASH is committed to advancing SCD and sickle cell trait research and has developed a list of ASH Priorities for Sickle Cell Disease and Sickle Cell Trait, which includes ASH’s Sickle Cell Research Priorities.
ASH continues to take steps to advance SCD research and is currently exploring opportunities to enhance SCD clinical research to:
- Improve outcomes for individuals with SCD
- Facilitate innovative approaches to clinical trials research
- Expedite drug development
ASH Research Collaborative
The ASH Research Collaborative (ASH RC) was established by the American Society of Hematology (ASH) in 2018 to foster collaborative partnerships to accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. The foundation of the ASH RC is its Data Hub, a technology platform that facilitates the exchange of information by aggregating in one place, and making available for inquiry, research-grade data on hematologic diseases.
The first research initiative of ASH RC is a Sickle Cell Disease (SCD) Clinical Trials Network (CTN), which will launch in 2019 to optimize the conduct of clinical trials research in SCD. The Network will leverage the Data Hub to collect key information and identify gaps that will help advance SCD research and treatment.
Other SCD Research-Focused Resourcesback to top
ASH Research Collaborative SCD Clinical Trials Network
The ASH Research Collaborative (ASH RC) SCD Clinical Trials Network is being launched with a mission of improving outcomes for individuals with SCD by expediting SCD therapy development and facilitating innovation in clinical trial research. To apply to become a Network site, submit a letter of intent by January 31, 2019 to SCD-CTN@ashresearchcollaborative.org.back to top
SCD Access to Care
ASH is committed to ensuring that individuals with SCD have access to high quality of care and is currently in the process of developing and implementing a multi-pronged strategy to expand health care professional education and training on SCD. Activities are aimed at four key audiences: hematologists, patients, hospitalists, and primary care clinicians. The Society is also working closely with the Emergency Department Sickle Cell Care Coalition to support their efforts to improve emergency care of individuals with SCD.
ASH is also developing and implementing five new clinical practice guidelines on the management of acute and chronic complications of SCD. Publication of the guidelines is anticipated in 2019.
The following resources were developed by ASH for those working to improve outcomes for persons with SCD.
back to top
- Resources for Clinicians: From developing pocket guides and clinical guidelines to producing SCD-related webinars, ASH is committed to helping those who treat SCD patients provide quality care, continue their professional development, and enhance their knowledge and expertise.
- Resources for Patients: An overview of sickle cell disease for patients, including an explanation of the difference between sickle cell trait and sickle cell anemia.
SCD Policy Priorities
ASH works with federal agencies and the U.S. Congress to help enhance and expand government activities in SCD research, training, and services. ASH is working with congressional champions to raise awareness for SCD on Capitol Hill, to have legislation introduced to strengthen current federal SCD programs, and to increase funding for federal SCD programs. ASH also continues to encourage the Centers for Medicare & Medicaid Services (CMS) to test innovative payment models for SCD care delivered by health care professionals.View SCD policy news
SCD-focused advocacy information and tools:back to top
ASH is focused on raising awareness of SCD globally by partnering with global organizations to build SCD-focused education. ASH is currently exploring the development of a consortium of African countries to address newborn screening for SCD. The consortium would introduce standard-of-care practices for screening and early intervention therapies at participating institutions, with the goal of decreasing childhood mortality rates for SCD.
The State of Sickle Cell Disease
This short documentary about sickle cell disease, set in sub-Saharan Africa, addresses the need for newborn screening and counters the prevailing myths about SCD.back to top
Sickle Cell Trait Resourcesback to top
If you are interested in learning more about the Sickle Cell Disease Initiative, please contact Sickle Cell Disease Policy and Programs Coordinator Karina Ngaiza at email@example.com
back to top